MarginsXMarginsX
Home › Data Desk › 4D Molecular Therapeutics Inc. has about 2.8 months of cash at its recent burn

MarginsX Data Desk · Quarterly results · Late-stage clinical trials · At-the-market offering · FDA approval

4D Molecular Therapeutics Inc. has about 2.8 months of cash at its recent burn

The 10-Q that 4D Molecular Therapeutics Inc. (FDMT) filed on Nov 12, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 12, 2026.

Line chart of 4D Molecular Therapeutics Inc. (FDMT) daily closes from Jul 6, 2026 to Nov 12, 2026, with the results filing on Nov 12, 2026 marked.

Revenue and margins

Revenue was $4.1M. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

The net loss was $78.1M. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

Balance sheet

Cash was $39.1M at Sep 30, 2026, against $70.4M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Total debt was $19.7M, against $19.6M at Jun 30, 2026. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

Shares outstanding were 56.4 million, against 55.2 million at Jun 30, 2026, a rise of 2.1%. (SEC XBRL company facts, 10-Q, Nov 12, 2026)

At its recent quarterly burn of $41.6M, that cash lasts about 2.8 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

The stock

The Nasdaq screener puts its market value at $683.0M. (Nasdaq stock screener, Nov 13, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/FDMT)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
Name4D Molecular Therapeutics Inc.Source2026-11-13
Runway2.8 monthsSource2026-09-30
Form10-QSource2026-11-12
Who4D Molecular Therapeutics Inc. (FDMT)Source2026-11-13
SymbolFDMTSource2026-11-13
FiledNov 12, 2026Source2026-11-12
Period endSep 30, 2026Source2026-11-12
Revenue4,145,000 USDSource2026-11-12
Net loss78,056,000 USDSource2026-11-12
Net income-78,056,000 USDSource2026-11-12
Cash39,104,000 USDSource2026-09-30
Cash prior70,372,000 USDSource2026-08-13
Prior endJun 30, 2026Source2026-08-13
Debt19,679,000 USDSource2026-11-12
Debt prior19,587,000 USDSource2026-08-13
Shares56,374,519 sharesSource2026-11-12
Shares prior55,214,097 sharesSource2026-08-13
Dilution0.021 %Source2026-11-12
Burn abs41,571,000 USDSource2026-09-30
Burn-41,571,000 USDSource2026-09-30
Cap683,036,455 USDSource2026-11-13

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS